IPSOGEN commitment in blood cancer

Since its creation in 1999, IPSOGEN designs, manufactures and markets molecular assays with proven expertise in identifying and translating key discoveries into essential tests intended to support personalized approach to cancer treatment.

More than 80 product references developped by IPSOGEN are used routinely in 61 countries for the diagnosis, prognosis and monitoring (or treatment follow-up) of thousands of patients with leukemia, including its least common forms :

• Acute Myeloid Leukemia
  
  

• Acute Lymphoblastic Leukemia (including Acute Promyelocytic Leukemia)
  
  

• Chronic Lymphocytic Leukemia and
  
  

• Subtypes of MyeloProliferative Neoplasms: Chronic Myeloid Leukemia, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis.